Literature DB >> 23041228

Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.

Carmen Blanco-Aparicio1, Amancio Carnero2.   

Abstract

PIM proteins belong to a family of ser/thr kinases composed of 3 members, PIM1, PIM2 and PIM3, with greatly overlapping functions. PIM kinases are mainly responsible for cell cycle regulation, antiapoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway. PIM kinases have been found to be upregulated in many hematological malignancies and solid tumors. Although these kinases have been described as weak oncogenes, they are heavily targeted for anticancer drug discovery. The present review summarizes the discoveries made to date regarding PIM kinases as driving oncogenes in the process of tumorigenesis and their validation as drug targets.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23041228     DOI： 10.1016/j.bcp.2012.09.018

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  45 in total

1.  A Novel Cinnamon-Related Natural Product with Pim-1 Inhibitory Activity Inhibits Leukemia and Skin Cancer.

Authors:  Jong-Eun Kim; Joe Eun Son; Hyein Jeong; Dong Joon Kim; Sang Kwon Seo; Eunjung Lee; Tae Gyu Lim; Jong Rhan Kim; Hanyong Chen; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  Cancer Res       Date:  2015-05-06       Impact factor: 12.701

2.  Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Authors:  Ralf Buettner; Corey Morales; Enrico Caserta; Estelle Troadec; Emine G Gunes; Domenico Viola; Jihane Khalife; Hongzhi Li; Jonathan J Keats; Austin Christofferson; Xiwei Wu; Timothy W Synold; Joycelynne Palmer; James F Sanchez; Alexander Pozhitkov; Nagarajan Vaidehi; Guido Marcucci; Amrita Krishnan; Michael A Rosenzweig; Flavia Pichiorri; Steven T Rosen
Journal:  Blood Adv       Date:  2019-04-09

3.  Pim kinase inhibitors for the treatment of cancer and possibly more.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-05-01       Impact factor: 4.345

4.  Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.

Authors:  Yu-Qian Zhao; Yi-Qiong Yin; Jie Liu; Gui-Hua Wang; Jian Huang; Ling-Juan Zhu; Jin-Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

5.  Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.

Authors:  Matthew T Burger; Wooseok Han; Jiong Lan; Gisele Nishiguchi; Cornelia Bellamacina; Mika Lindval; Gordana Atallah; Yu Ding; Michelle Mathur; Chris McBride; Elizabeth L Beans; Kristine Muller; Victoriano Tamez; Yanchen Zhang; Kay Huh; Paul Feucht; Tatiana Zavorotinskaya; Yumin Dai; Jocelyn Holash; Joseph Castillo; John Langowski; Yingyun Wang; Min Y Chen; Pablo D Garcia
Journal:  ACS Med Chem Lett       Date:  2013-10-15       Impact factor: 4.345

6.  The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Authors:  S Agarwal; J U Kazi; S Mohlin; S Påhlman; L Rönnstrand
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

7.  DNA Methylation-Derived Immune Cell Profiles, CpG Markers of Inflammation, and Pancreatic Cancer Risk.

Authors:  Dominique S Michaud; Mengyuan Ruan; Devin C Koestler; Lola Alonso; Esther Molina-Montes; Dong Pei; Carmen J Marsit; Immaculata De Vivo; Núria Malats; Karl T Kelsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-19       Impact factor: 4.254

8.  Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate.

Authors:  Leon Harrington; Stephen Cheley; Leila T Alexander; Stefan Knapp; Hagan Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-05       Impact factor: 11.205

9.  Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells.

Authors:  Zhenhai Yu; Xiaoping Zhao; Liangqian Huang; Teng Zhang; Fajun Yang; Lei Xie; Shaoli Song; Ping Miao; Li Zhao; Xiaoguang Sun; Jianjun Liu; Gang Huang
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

10.  STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.

Authors:  Daniel Ribeiro; Alice Melão; Ruben van Boxtel; Cristina I Santos; Ana Silva; Milene C Silva; Bruno A Cardoso; Paul J Coffer; João T Barata
Journal:  Blood Adv       Date:  2018-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.